急性冠状动脉综合征的抗血小板治疗进展  

Development of Antiplatelet Therapy for Acute Coronary Syndrome

作　　者：周召锋[1] 吴春阳[1] 

机构地区：[1]东南大学医学院附属盐城医院心内科,江苏盐城224001

出　　处：《心血管病学进展》2015年第5期646-650,共5页Advances in Cardiovascular Diseases

基　　金：盐城市科技计划项目(YK2014063)

摘　　要：抗血小板治疗尤其是阿司匹林联合氯吡格雷的双联抗血小板治疗,在急性冠状动脉综合征的治疗中起到非常重要的作用;由于氯吡格雷治疗的个体差异性及更强抗栓治疗获益的需求,新的P2Y12受体拮抗剂如替格瑞洛、普拉格雷等被不断研发,且被更多的循证医学证实更有效并应用于临床实践。同时静脉制剂的研发,对急诊经皮冠状动脉介入术提供了快速有效的抗血小板治疗。未来,如何降低心血管患者缺血事件的发生率及避免增加出血事件发生率,仍是抗血小板药物研究的重点及方向。Dual-antiplatelet therapy with aspirin and a P2Y12 receptor antagonist is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. Current therapy with aspirin plus clopidogrel is one of the most important options, however with the important limitation of individual variation affecting clinical success. Increasing evidence shows that the novel oral P2Y12 receptor antagonist such as ticagrelor and prasugrel provides better efficacy than clopidogrel. Meanwhile, venous admin- istration provides faster and greater platelet inhibition for primary percutaneous coronary intervention. It＇ s still the main focus for antiplatelet drug development and research to balance ischemic events and avoid bleeding.

关 键 词：抗血小板治疗 急性冠状动脉综合征 P2Y12受体拮抗剂 GPⅡb/Ⅲa受体拮抗剂 蛋白酶激活受体1拮抗剂 

分 类 号：R541.4[医药卫生—心血管疾病]